Oxazine 1 perchlorate
(Synonyms: 噁嗪高氯酸盐) 目录号 : GC30260
Oxazine1perchlorate是一种对称阳离子染料(λex=653nm，λem=666nm)。
Cas No.:24796-94-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | Oxazine 1 perchlorate doped liquid crystal samples are prepared from a pair of quartz sheets sandwiched exactly at known gap and sealed. The introduction of the dissolved Oxazine 1 perchlorate in nematic solvents is achieved by capillary action. Oxazine 1 perchlorate concentrations are chosen to be 1×10−5 M for all the liquid samples. Oxazine 1 perchlorate is studied in the nematic media up to a concentration of about 0.1%, w/w. The absorption spectra of Oxazine 1 perchlorate are recorded on a double beam spectrophotometer over a wavelength range 300 to 800 nm combined with a cell temperature controller[1]. |
References: [1]. Gilani AG, et al. Estimation of ground- and excited-state dipole moments of oxazine 1 in liquid and liquid crystalline media. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jun;79(1):148-55. | |
Oxazine 1 perchlorate is a symmetric cationic dye (λex=653 nm, λem=666 nm).
Oxazine 1 perchlorate (OX1) absorbs and emits light at about 653 and 666 nm in dilute aqueous solutions, respectively. It is soluble over a very wide range of polar solvents. The optical spectrum of Oxazine 1 perchlorate typically possesses an intense absorption band (λmax), which is neighbored by a shoulder at shorter wavelengths. Oxazine 1 perchlorate appears to exist almost in its monomeric form at concentrations below about 1×10-4 M in aqueous solutions. As it is expected, similar to polar ordinary liquid solvents, Oxazine 1 perchlorate shows only single fluorescence band in polar anisotropic media[1].
[1]. Gilani AG, et al. Estimation of ground- and excited-state dipole moments of oxazine 1 in liquid and liquid crystalline media. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Jun;79(1):148-55.
| Cas No. | 24796-94-9 | SDF | |
| 别名 | 噁嗪高氯酸盐 | ||
| Canonical SMILES | CCN(C1=CC2=[O+]C3=C(C=CC(N(CC)CC)=C3)N=C2C=C1)CC.O=Cl(=O)([O-])=O | ||
| 分子式 | C20H26ClN3O5 | 分子量 | 423.89 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3591 mL | 11.7955 mL | 23.591 mL |
| 5 mM | 0.4718 mL | 2.3591 mL | 4.7182 mL |
| 10 mM | 0.2359 mL | 1.1796 mL | 2.3591 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives
A series of novel heterocyclic structures, namely 1,3-oxazines, 1,3-thiazines and 2,4-diaminopyrimidines, were designed and synthesised. The bioassay tests demonstrated that, among these analogues, 2,4-diaminopyridine derivatives showed significant antiproliferative activity against different human cancer cell lines (A2780, SiHa, HeLa, MCF-7 and MDA-MB-231). Pyrimidines substituted with N2 -(p-trifluoromethyl)aniline, in particular, displayed a potent inhibitory effect on the growth of cancer cells. Structure-activity relationships were also studied from the aspects of stereochemistry on the aminodiol moiety as well as exploring the effects of substituents on the pyrimidine scaffold.
3-Bromomethyl-3-ethyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4-dione
In the title compound, C10H14BrNO3, the six-membered lactone ring is in a boat conformation, with the two carbonyl groups cis to one another across the boat basal plane. C-H...O hydrogen bonds and weak C-H...Br interactions stabilize the crystal structure.
Polymer-Supported Syntheses of Heterocycles Bearing Oxazine and Thiazine Scaffolds
In this review, we summarize synthetic approaches to preparing single or fused oxazine and thiazine derivatives using solid-phase synthesis (SPS). The literature survey revealed that diverse compounds bearing variously functionalized 1,2-oxazine, 1,3-oxazine, or 1,4-oxazine scaffolds and the corresponding thiazines are accessible by SPS. The latest contributions involving the stereoselective polymer-supported syntheses of morpholines indicate that the field is continuing to expand.
The Construction of Polycyclic Pyridones via Ring-Opening Transformations of 3-hydroxy-3,4-dihydropyrido[2,1- c][1,4]oxazine-1,8-diones
This work describes the synthesis of 3-hydroxy-3,4-dihydropyrido[2,1-c][1,4]oxazine-1,8-diones, their tautomerism, and reactivity towards binucleophiles. These molecules are novel and convenient building-blocks for the direct construction of biologically important polycyclic pyridones via an oxazinone ring-opening transformation promoted with ammonium acetate or acetic acid. In the case of o-phenylenediamine, partial aromatization of the obtained heterocycles proceeded to form polycyclic benzimidazole-fused pyridones (33-91%).
Structure-Based Drug Discovery of N-(( R)-3-(7-Methyl-1 H-indazol-5-yl)-1-oxo-1-((( S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3- d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine
Structure-based drug design enabled the discovery of 8, HTL22562, a calcitonin gene-related peptide (CGRP) receptor antagonist. The structure of 8 complexed with the CGRP receptor was determined at a 1.6 ? resolution. Compound 8 is a highly potent, selective, metabolically stable, and soluble compound suitable for a range of administration routes that have the potential to provide rapid systemic exposures with resultant high levels of receptor coverage (e.g., subcutaneous). The low lipophilicity coupled with a low anticipated clinically efficacious plasma exposure for migraine also suggests a reduced potential for hepatotoxicity. These properties have led to 8 being selected as a clinical candidate for acute treatment of migraine.